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Abstract (J Korean Assoc Oral Maxillofac Surg 2018;44:220-224)
Objectives: The aim of this study was to determine the incidence and characteristics of second primary malignancy (SPM) in patients with head and 
neck squamous cell carcinoma treated at a tertiary care hospital.
Materials and Methods: We retrospectively reviewed the medical records of 221 patients who underwent surgery with or without adjuvant treat-
ment for head and neck cancer from 2000 to 2002. Data of age, sex, risk factors, sites of primary and SPM, TNM stage of primary tumor, incidence of 
SPM, and survival were collected from medical charts.
Results: Eighteen patients developed SPM during a median follow-up of 67 months, with an overall incidence of 8.14%. In addition, 77.7% of SPMs 
occurred in the oral cavity, followed by 11% in the lungs. The 5-year overall survival after the diagnosis of SPM in the head or neck was 70%, com-
pared to 30% for SPM in other body regions.
Conclusion: Considering a high incidence of SPM, i.e., 8.14%, in a mean follow-up period of 67 months suggests the need for long-term follow-up. 
Since treatment of SPM has shown an acceptable survival rate, early detection and curative therapy should be emphasized.
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I. Introduction
Head and neck cancer patients are declared tumor-free af-
ter surgery alone or with adjuvant treatment. Most reputable 
centers advocate a follow-up plan that emphasizes a monthly 
visit in the first year, bimonthly in the second year, quarterly 
in the third year, and every six months in the fifth year of 
survivorship1. After five years of survivor-ship, the patient 
is considered disease-free. We follow the patients up to five 
years, and then no follow-ups are recommended unless need-
ed. Recent literature showed that up to 24% of head and neck 
cancer patients will develop a second primary lesion2. The 
incidence of second primary malignancy (SPM) was mostly 
found in patients who continued to consume carcinogenic 
agents and/or smoking3. 
Locoregional control of head and neck cancer has im-
proved in the last couple of decades; however, long-term 
survival has shown minimal improvement due to distant 
metastasis and SPM4,5. All SPMs have been shown to have a 
significant impact on survival6. In Pakistan, this critical issue 
has not been addressed in any study to date. We hypothesize 
based on anecdotal data that incidence of SPM in our popula-
tion could be higher than in Western populations. Hence, we 
retrospectively reviewed our patients over a defined period 
to determine the incidence of SPM and patient outcomes in 
terms of survival. 
II. Materials and Methods
In the present study, the files of 221 newly diagnosed pa-
tients with head and neck squamous cell carcinoma (HNSCC) 
who underwent surgery with or without adjuvant therapy at 
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The Aga Khan University Hospital from January 2000 to 
December 2002 were retrospectively reviewed. Of these, 
18 patients developed SPM during the follow-up period and 
composed our study cohort.
Patients who were inoperable, underwent surgery outside of 
our hospital, or refused primary surgery were excluded from 
the study. All patients had a minimum of 10 years of follow-
up at the time of data collection. Since this study consisted 
only of patient chart review, according to institutional policy, 
exemption was granted by the Ethical Review Committee of 
The Aga Khan University Hospital (2601-Sur-ERC-13).
SPM was defined using the criteria established by War-
ren7 and Hong et al.8, who stated that the tumors should be 
histologically malignant and at least 2 cm apart or developed 
at least 3 years after the original tumor. In addition, any new 
malignancy of the lung should be considered SPM if it is a 
single lesion and histologically different, and the possibility 
of metastatic carcinoma has been excluded, unless the tumor 
occurred after 3 years, which classifies it a SPM based on the 
above definition. Tumors were also classified as synchronous 
or metachronous: a synchronous tumor was defined as oc-
curring within 6 months after the diagnosis of primary tumor, 
and metachronous malignancy was defined as occurring after 
6 months of follow-up.
All patients had a complete medical history taken and head 
and neck examination performed on every outpatient follow-
up. Chest x-rays were performed annually; other complemen-
tary examinations were performed based on symptoms and 
clinical findings.
All patients that fulfilled the inclusion criteria were includ-
ed in the study. Files were reviewed and Performa were filled. 
Follow-ups were recorded for all patients, and incidence was 
determined in terms of frequency/percentage. Survival was 
calculated using the Kaplan-Meier curve. Data were analyzed 
using IBM SPSS Statistics (ver. 20; IBM Co., Armonk, NY, 
USA).
III. Results
The demographic data of patients and primary tumor-
related details are shown in Table 1. A total of 18 patients was 
included in our study. The median age was 53.5±12.0 years. 
Twelve patients (66.7%) were male and six were female. All 
patients had some type of addiction such as tobacco or betel 
nut. Most common site of primary tumor was the oral cav-
ity and was observed in 15 patients (83.3%). We performed 
pathological staging of the primary tumor using American 
Joint Committee on Cancer staging system seventh edition9; 
8 patients (44.4%) had stage IV disease, and stage II disease 
was observed in 7 individuals (38.9%).
All patients underwent surgery as their primary treatment 
modality, and eight patients received adjuvant radiotherapy. 
All patients participated in regular follow-up. Median time 
to SPM occurrence was 67 months. Sixteen of 18 patients 
developed SPM in the head and neck, whereas only two pa-
tients developed SPM in a non-head and neck site. Of the 16 
patients with SPM in the head and neck, 14 were treated sur-
gically, whereas two had treatment with non-surgical modal-
ity with curative intent.
The overall incidence of SPM was 8.14%, as shown in 
Table 2. In patients who developed SPM in the head and neck 
area, oral cavity was the most common site, observed in 14 
patients (77.8%).(Table 3) However, larynx and oral cavity 
were each also a site of SPM. 
Kaplan-Meier curve was used to determine the 5-year and 
10-year survival rates (Fig. 1); approximately 70% at 5 years 
and gradually declined to 38% at 10 years for all head and 
Table 1. Characteristics of patients with second primary malig-
nancy
Characteristic Value
Gender
Male
Female
Median age (yr)
Addiction
Tobacco
Betel nut
More than one
Primary tumor site
Oral cavity
Hypopharynx
Larynx
Primary pathologic T stage
T1
T2
T3
T4
Primary pathologic N stage
N0
N1
N2
N3
Primary pathologic stage
Stage I
Stage II
Stage III
Stage IV
12 (66.7)
6 (33.3)
53.5±12.0
6 (33.3)
8 (44.4)
4 (22.2)
15 (83.3)
2 (11.1)
1 (5.6)
1 (5.6)
8 (44.4)
2 (11.1)
7 (38.9)
14 (77.8) 
2 (11.1)
2 (11.1)
0
1 (5.6)
7 (38.9)
2 (11.1)
8 (44.4)
Values are presented as number (%) or mean±standard deviation.
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neck SPMs.
IV. Discussion
Although locoregional control of HNSCC has improved 
in the last few decades, SPM and distant metastasis are still 
important aspects that limit survival10,11. Vikram et al.6 re-
ported failure patterns of HNSCC, revealing that SPM and 
distant metastasis mostly occurred in the first 2 to 3 years of 
primary treatment, after which the incidence of distant me-
tastasis decreased with time12. Conversely, the incidence of 
SPM remained static over time13,14. The data from developing 
countries have consistently demonstrated a lower frequency 
of SPMs, which could be attributed to the limited number 
of studies published; Mehdi et al.15 reported an incidence of 
1.14%, compared to an incidence of 10% to 40% in previous 
studies14,16,17. In the present study, the overall incidence was 
8.14%, which was comparable with international data.
The theory of field cancerization was first introduced by 
Slaughter and his colleagues in 1953, and refers to continuous 
exposure of the upper aerodigestive tract to carcinogens that 
may result in multiple precancerous changes and potentially 
lead to a malignant change. Patients using alcohol and tobac-
co have been shown to have the greatest risk for SPMs11,13. In 
Asians, betel quid chewing is also a risk factor for SPM18. In 
the present study, all patients were using tobacco, betel quid, 
or both. However, none of the patients used alcohol, which 
could be a limitation due to cultural restraints; the majority 
of patients may be hesitant to admit consuming alcohol. Be-
cause of the retrospective nature of this study, exact details 
of continued addictions after treatment of the primary malig-
nancy could not be confirmed.
Reportedly, the most common site of SPM is the head and 
neck, followed by lungs and esophagus14,19. Hsu et al.20 in 
their study of 18 patients with a SPM showed that 70.2% of 
SPMs developed in the head and neck, whereas 27.7% oc-
curred in non-head and neck sites. Similarly, in our study, the 
most frequent location of SPM was head and neck (89%), fol-
lowed by lungs (11%). The median time interval to develop 
a SPM in the present study was 67 months, and other studies 
have reported a median time interval of 48 to 72 months1,20. 
Furthermore, in our study, the 5-year survival in patients 
with head and neck SPM was 70% and was comparable with 
other reports1,21. Similarly, in a previous study, a 10-year 
survival of 39% was reported1, which was nearly in agree-
ment with the results from our study (38%). The decline in 
Table 2. Characteristics of second primary tumor
Characteristic Value
Incidence of SPM (%)
Overall
5-year SPM rate
10-year SPM rate
Time interval (mo)
Site of SPM
Head and neck
Non-head and neck
Pathologic stage of SPM (head and neck)
Stage I
Stage II
Stage III
Stage IV
5-year survival rate (%)
Head and neck
Non-head and neck
8.14
3.6
4.5
67 (0-121)
16 (88.9)
2 (11.1)
2 (11.1) 
3 (16.7) 
7 (38.9) 
4 (22.2) 
70
30
(SPM: second primary malignancy)
Values are presented as %, median (range), or number (%).
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Table 3. Second primary malignancy sites
Site Value
Head and neck
Oral cavity
Oropharynx
Hypopharynx
Larynx
Non-head and neck
Lung
Esophagus
14 (77.8)
1 (5.6)
0
1 (5.6)
2 (11.1)
-
Values are presented as number (%).
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Fig. 1. Survival functions. (SPM: second primary malignancy)
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survival observed in long-term follow-up can be attributed to 
the development of SPM; the median time to develop another 
tumor was 67 months.
Patients with SPM have a relatively long-term survival, 
and many patients do well considering it is their second tu-
mor. Therefore, efforts should be made to implement regular 
follow-ups for early diagnosis13. In our study, many patients 
were diagnosed when they were not monitored because 
they had completed their 5 years of follow-up. We suggest 
that treated head and neck cancer patients be followed up 
throughout their lives to detect early SPMs, which should be 
treated aggressively to attain maximum benefit. Despite the 
better outcomes observed in this study, multi-institutional 
data are required to confirm the results.
In our report, a series of patients was surgically treated for 
HNSCC in a single tertiary care hospital. This study had sev-
eral strengths and limitations. The main strength of the study 
was that all patients with HNSCC in a given period were pri-
marily treated with surgery. Secondly, because patients were 
primarily treated with surgery, the impact of radiation on de-
velopment of SPM was minimized. Conversely, study limita-
tions include the retrospective study design, missing records, 
and small sample size.
V. Conclusion
Based on SPM patterns, we suggest that patients with pre-
viously treated HNSCC should receive long-term follow-up 
for early detection of SPM. Although the 10-year survival 
decreases by 50% due to development of SPM, an acceptable 
survival rate can still be achieved by early detection of SPM 
with regular long-term follow-up and appropriate subsequent 
curative therapy. 
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